STOCK TITAN
  1. Home
  2. Sec-filings
  3. ADVB
  4. [8-K] Advanced Biomed Inc. Reports Material Event

Advanced Biomed (NASDAQ: ADVB) secures US$600,000 six-month unsecured loan

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Advanced Biomed Inc. entered into an unsecured Loan Agreement with Jie Wang under which the lender provided a US$600,000 short-term loan. The loan carries a 10% annual interest rate, runs for six months from the disbursement date, and may be extended once for an additional six months by mutual written agreement.

The company must repay the full US$600,000 principal plus accrued interest on or before the maturity date but can prepay at any time without penalty, with partial prepayments applied first to interest and then principal. Advanced Biomed plans to use the loan proceeds for operations, and the agreement is governed by New York law.

Positive

  • None.

Negative

  • None.

Insights

Advanced Biomed adds a small unsecured, high-rate, six-month loan for operations.

Advanced Biomed Inc. obtained a US$600,000 unsecured loan from Jie Wang at a 10% annual interest rate, with a six-month term from the disbursement date and an option to extend once for another six months by mutual agreement.

The loan is earmarked for operations, suggesting near-term liquidity needs are being met through debt rather than equity in this instance. The ability to prepay without penalty and the unsecured nature help keep flexibility, though the interest rate is relatively high for a short-dated facility.

Because the loan is short term, refinancing or repayment decisions will become important by the maturity date defined in the agreement. Future company filings may show whether the loan is repaid on schedule, extended for an additional six months, or replaced with other financing.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Loan principal US$600,000 Principal amount lent under the Loan Agreement
Interest rate 10% per annum Annual interest on the loan from disbursement date
Initial loan term 6 months Term from the disbursement date to maturity
Possible extension 6 months Additional term available by mutual written agreement
Material Definitive Agreement regulatory
"Item 1.01 Entry into a Material Definitive Agreement."
A material definitive agreement is a legally binding contract that creates major, long‑term obligations or rights for a company, such as loans, asset sales, mergers, or supplier deals. Think of it like a mortgage or lease for a business: it can change future cash flow, risk and control, so investors watch these agreements closely because they can materially affect a company’s value, financial health and stock price.
principal amount financial
"the Lender lent to the Company a principal amount of Six Hundred Thousand United States Dollars"
The principal amount is the original sum of money that is borrowed, lent, or invested before any interest, fees, or returns are added. It matters to investors because interest charges, scheduled repayments, and total return are calculated from that base amount — think of it as the price tag on which future costs or gains are built. Knowing the principal helps you compare deals and predict cash flows and risk.
Maturity Date financial
"The term of the Loan is six (6) months from the Disbursement Date (the "Maturity Date")."
The maturity date is the specific day when a loan, bond, or investment reaches its full term and the borrower must repay the borrowed amount in full. It is important for investors because it indicates when they will receive their initial money back and can plan their future financial steps accordingly. Think of it as the due date for a loan or the day a gift card or coupon expires.
unsecured financial
"The Loan is unsecured."
Unsecured describes a loan, bond, or claim that is not backed by specific assets or collateral; if the borrower fails to pay, creditors must rely on the borrower’s general promise rather than seizing a pledged asset. For investors this usually means higher risk and potentially higher yield, because unsecured holders stand behind secured creditors in repayment priority—think of lending money to someone without a pledged item to repossess if they don’t pay.
governed by the laws of the State of New York regulatory
"The Loan Agreement is governed by the laws of the State of New York"
Understanding 8-K Material Events →
false 0001941029 0001941029 2026-04-13 2026-04-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

 

April 13, 2026

Date of Report (Date of earliest event reported)

 

Advanced Biomed Inc.

(Exact name of Company as specified in its charter)

 

Nevada   001-42548   87-2177170
(State or other jurisdiction
of Incorporation)		  
 		 (Commission File Number)
 		  
 		 (IRS Employer
Identification Number)

 

No. 689-85 Xiaodong Road, Yongkang District

Tainan City, Taiwan 

(Address of principal executive offices)

 

886-6-3121716

(Registrant’s telephone number including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   ADVB   The Nasdaq Stock Market LLC

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On April 13, 2026, Advanced Biomed Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Jie Wang (the “Lender”), pursuant to which the Lender lent to the Company a principal amount of Six Hundred Thousand United States Dollars (US$600,000) (the “Loan”).

 

The Loan bears interest at an annual rate of ten percent (10%) per annum, accruing from the date the Loan proceeds are disbursed to the Company (the “Disbursement Date”). The term of the Loan is six (6) months from the Disbursement Date (the “Maturity Date”). Upon the mutual written agreement of the parties, the term may be extended for six (6) additional months.

 

On or before the Maturity Date, the Company is required to repay the full principal amount of US$ 600,000, together with all accrued and unpaid interest. The Company may prepay the Loan, in whole or in part, at any time without penalty or premium, with any partial prepayment applied first to accrued interest and then to outstanding principal.

 

The Loan is unsecured. The Loan Agreement is governed by the laws of the State of New York, and any disputes arising thereunder shall be resolved in the courts of the State of New York.

 

The Company plans to use the proceeds from the Loan for operation.

 

The foregoing description of the Loan Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Loan Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 9.01 Financial Statement and Exhibits.

 

Exhibit No.   Description
10.1   Loan Agreement, dated April 13, 2026, between Advanced Biomed Inc. and Jie Wang.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

  

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Advanced Biomed Inc.
     
Date: April 14, 2026 By: /s/ Yi Lu
    Yi Lu
    Chief Executive Officer

 

2

 

Source: View Original Filing on SEC EDGAR

FAQ

What did Advanced Biomed Inc. (ADVB) announce in this 8-K filing?

Advanced Biomed Inc. disclosed a new unsecured loan agreement with Jie Wang for US$600,000. The loan bears 10% annual interest, has a six-month term from disbursement, and may be extended once for another six months by mutual written agreement.

What are the key terms of Advanced Biomed’s US$600,000 loan?

The loan principal is US$600,000, with a 10% per annum interest rate starting on disbursement. It matures in six months, with a possible additional six-month extension, and must be repaid with all accrued interest on or before the maturity date.

Is the new US$600,000 loan to Advanced Biomed (ADVB) secured?

The loan to Advanced Biomed Inc. is explicitly described as unsecured, meaning it is not backed by specific collateral. The agreement is governed by the laws of the State of New York, with disputes to be resolved in New York courts.

How will Advanced Biomed Inc. use the US$600,000 loan proceeds?

Advanced Biomed Inc. states that it plans to use the US$600,000 loan proceeds for operation. This indicates the funds are intended to support the company’s ongoing business activities rather than a specific acquisition or capital project.

Can Advanced Biomed (ADVB) prepay the US$600,000 loan without penalty?

Yes. Advanced Biomed Inc. may prepay the loan at any time, in whole or in part, without penalty or premium. Any partial prepayment is applied first to accrued interest and then to the outstanding principal balance.

Who is the lender in Advanced Biomed Inc.’s new loan agreement?

The lender named in the agreement is Jie Wang, who provided Advanced Biomed Inc. with a principal amount of US$600,000. The relationship beyond being a contracting lender is not detailed in the disclosed terms.

Filing Exhibits & Attachments

4 documents

Agreements & Contracts

Other Documents